



Gp. 1806

#9  
5/13/93  
TCL

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ANDERSON, DARRELL R., *et al.*

Serial No. 07/978,891

Group Art Unit:

Filed: 13 November 1992

Examiner: Schwadron, R.

RECEIVED

Title: THERAPEUTIC APPLICATION OF  
CHIMERIC ANTIBODY TO HUMAN B  
LYMPHOCYTE RESTRICTED  
DIFFERENTIATION ANTIGEN FOR  
TREATMENT OF B CELL  
LYMPHOMA

MAY 11 1993

May 3, 1993  
La Jolla, CA

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §§1.56 and 1.99, Applicants hereby make the following documents of record in the above-identified application. In accordance with 37 C.F.R. §1.97(b), the filing of this Information Disclosure Statement shall not be construed to be material to patentability as defined in §1.56(b). In accordance with 37 C.F.R. §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made. Additionally, Applicants neither admit nor suggest that no other material information may exist, such that the submission of the Information Disclosure Statement should not be construed to indicate that a thorough search should not be conducted by the Examiner. Furthermore, unless specifically designated as such, no reference cited in the Information Disclosure Statement is admitted to be or is construed to be "prior art."


Markings that may exist on the documents are to be accorded no significance or import; to the extent that such markings may exist, these are to be construed as

extraneous. Additionally, the order of the following documents is to be accorded no significance or import as the order thereof is completely fortuitous.

Copies of the documents listed on the accompanying IDS Document List (submitted in duplicate), are enclosed herewith. It is respectfully requested that these documents be: (1) fully considered by the Patent and Trademark Office during the examination of this application; and (2) presented on any patent which may issue in this application. Applicants respectfully request that a copy of the IDS Document List, as considered and initialed by the Examiner, be returned with the next communication.

The Office is hereby authorized to charge our Deposit Account No. 09-0017 for any fees associated with the Information Disclosure Statement. A duplicate of this sheet is enclosed.

Respectfully submitted,

  
Richard P. Burgoon, Jr,  
Registration No. 34,787  
Intellectual Property Counsel  
IDEC Pharmaceuticals Corporation  
11099 N. Torrey Pines Road, #160  
La Jolla, CA 92037  
(619) 458-0600